Sergio Stagnaro, Biophysical-Semeiotic Research Laboratory
25 October 2005
In my opinion, for all women (and men!), apart from family history (1), an original, objective, clinical assessement may be desirable that in a easy and reliable manner allows doctor to recognize the presence of maternally-inherited Oncological Terrain, conditio sine qua non of malignancy (2), without to follow with genetic testing, but ascertaining also breast cancer “real risk” in well-defined breast quadrant(s)in a quick way. In addition, testing for mutations of breast cancer susceptibility genes or for their diminished expression adds to our ability to assess breast cancer risk at an individual level. Really, we cannot localise in a (or more) mamma quadrant the possible breast cancer risk in BRCA 1 and BRCA 2 positive women (and men!). Biophysical Semeiotics (http://www.semeioticabiofisica.it, Breast Cancer in Practical Application, and Oncological Terrain) allows doctor to recognize firstly oncological terrain in a "quantitative" way, and then, bu “not” in all cases, of course, breast cancer real risk: individuals with oncological terrain do not show generally real risk in all biological systems (3). Interestingly, the absence of both Oncological Terrain and breast oncological “Real Risk” , the later detected always in a subject with Oncological Terrain, excludes beyond every doubt the possibility of occurrence of breast cancer (2, 3). As a consequence, we can perform nowadays an efficacious clinical, primary prevention of breast cancer (4), on very large scale, based on the Single Patient Based Medicine (5), as suggests also Planning for the EU public Health Portal at URL:
1) Saxena S. et al. Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India-A cross-sectional study. World Journal of Surgical Oncology 2005, 3:67 doi:10.1186/1477-7819-3-67
2)Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico. Travel Factory SRL., Roma, 2004.
3) Stagnaro-Neri M., Stagnaro S. Cancro della mammella: : prevenzione primaria e diagnosi precoce con la percussione ascoltata. Gazz. Med. It.; Arch. Sc. Med. 152, 447, 1993.
4) Stagnaro S. Lettera aperta al Ministro della Salute, Prof. G. Sirchia, sulla prevenzione primaria clinica del cancro mammario.
http://bmj.bmjjournals.com/cgi/eletters?lookup=by_date&days=1#72216 27 August 2004
5) Stagnaro S., Stagnaro-Neri M. Single Patient Based Medicine.La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Travel Factory SRL., Roma, 2005. http://www.travelfactory.it/semeiotica_biofisica.htm
Bed-side evaluating breast cancer real risk.
25 October 2005
In my opinion, for all women (and men!), apart from family history (1), an original, objective, clinical assessement may be desirable that in a easy and reliable manner allows doctor to recognize the presence of maternally-inherited Oncological Terrain, conditio sine qua non of malignancy (2), without to follow with genetic testing, but ascertaining also breast cancer “real risk” in well-defined breast quadrant(s)in a quick way. In addition, testing for mutations of breast cancer susceptibility genes or for their diminished expression adds to our ability to assess breast cancer risk at an individual level. Really, we cannot localise in a (or more) mamma quadrant the possible breast cancer risk in BRCA 1 and BRCA 2 positive women (and men!). Biophysical Semeiotics (http://www.semeioticabiofisica.it, Breast Cancer in Practical Application, and Oncological Terrain) allows doctor to recognize firstly oncological terrain in a "quantitative" way, and then, bu “not” in all cases, of course, breast cancer real risk: individuals with oncological terrain do not show generally real risk in all biological systems (3). Interestingly, the absence of both Oncological Terrain and breast oncological “Real Risk” , the later detected always in a subject with Oncological Terrain, excludes beyond every doubt the possibility of occurrence of breast cancer (2, 3). As a consequence, we can perform nowadays an efficacious clinical, primary prevention of breast cancer (4), on very large scale, based on the Single Patient Based Medicine (5), as suggests also Planning for the EU public Health Portal at URL:
http://www.google.it/search?q=cache:U5A-DtWmRDsJ:europa.eu.int/comm/health/ph_information/documents/ev_20030710_co01_en.pdf+single+patient+based+medicine+and+stagnaro&hl=it&ie=UTF-8 Pg 36.
1) Saxena S. et al. Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India-A cross-sectional study. World Journal of Surgical Oncology 2005, 3:67 doi:10.1186/1477-7819-3-67
2)Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico. Travel Factory SRL., Roma, 2004.
http://www.travelfactory.it/semeiotica_biofisica.htm
3) Stagnaro-Neri M., Stagnaro S. Cancro della mammella: : prevenzione primaria e diagnosi precoce con la percussione ascoltata. Gazz. Med. It.; Arch. Sc. Med. 152, 447, 1993.
4) Stagnaro S. Lettera aperta al Ministro della Salute, Prof. G. Sirchia, sulla prevenzione primaria clinica del cancro mammario.
http://www.katamed.it/Notizia.asp?id=8094&lingua=IT&idcat=999;
http://xoomer.virgilio.it/piazzetta/professione/professione.htm
http://www.ilpungolo.com/site/leggi.asp?NWS=2390&IDS=10.
http://bmj.bmjjournals.com/cgi/eletters?lookup=by_date&days=1#72216 27 August 2004
5) Stagnaro S., Stagnaro-Neri M. Single Patient Based Medicine.La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Travel Factory SRL., Roma, 2005. http://www.travelfactory.it/semeiotica_biofisica.htm
Competing interests
Not declared